Venous thromboembolism impacts hundreds of thousands of medical and surgical patients each year1,2

Venous thromboembolism (VTE), including both deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common, sometimes lethal disorder that affects hospitalized and nonhospitalized patients, often recurs, is not always diagnosed, and can have long-term complications.3

It is believed that approximately 1 million VTE cases in the United States are reported each year, many of which represent recurrent disease.3

It is important to integrate VTE risk assessment into admission and transfer procedures, nursing/active interventions, and surgical care pathways to determine the risks of DVT and PE in your patients.

More than 250,000 patients are hospitalized for VTE (including DVT and PE) each year in the United States1,3

Approximately 67% of VTE cases are associated with a recent hospital admission

Only 50% of hospitalized patients at risk for VTE received prophylaxis prior to surgery5

  • Surgeries with a high risk for thrombosis include general, orthopedic, oncologic, neurosurgery, cardiovascular, and gynecologic6,7

Even modest decreases in antithrombin levels significantly increase VTE risk8,9

Patients with decreasing AT levels are at greater risk of experiencing a thrombotic episode, which underscores the importance of finding the balance between VTE risk and AT levels.8,9

Even plasma levels that are considered normal (between 86 and 100 IU/dL) pose a significant risk for VTE8

The risk of VTE, when stratified for unprovoked VTE,* is 6 times higher for those with AT levels between 61% and 75%8†

85% of patients with hereditary AT deficiency will have at least 1 thrombotic episode by age 50

  • Nearly 70% of these patients will have an event before the age of 3510

Risk of unprovoked VTE* increases with decreasing AT levels8†


Risk of unprovoked VTE increases with decreasing AT levels chart

AT and VTE risk fact sheet

VTE (including DVT and PE) impacts thousands of medical and surgical patients each year, making it one of the most common causes of hospital mortality.2,3 Download your copy of the AT and VTE risk fact sheet and see why it's important to achieve balance between VTE risk and AT levels.

The Caprini Risk Assessment Model

The Caprini Risk Assessment Model is a validated tool for assessing the occurrence of VTE among surgical patients11

  • The Caprini risk factor score includes 20 variables and is derived from a prospective study of 538 general surgery patients
  • Testing AT levels should be part of the standard preoperative coagulation panel in patients identified as being at high risk for VTE

IMPORTANT SAFETY INFORMATION


THROMBATE III® (antithrombin III [human]) is indicated in patients with hereditary antithrombin deficiency for treatment and prevention of thromboembolism and for prevention of perioperative and peripartum thromboembolism.

Hypersensitivity reactions may occur. Should evidence of an acute hypersensitivity reaction be observed, promptly interrupt the infusion and begin appropriate treatment.

Because THROMBATE III is made from human blood, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. There is also the possibility that unknown infectious agents may be present in the product.

Perform coagulation tests to avoid excessive or insufficient anticoagulation and monitor for bleeding or thrombosis. Measure functional plasma AT levels with amidolytic or clotting assays; do not use immunoassays.

In clinical studies, the most common adverse reactions (≥ 5% of subjects) were dizziness, chest discomfort, nausea, dysgeusia, and pain (cramps).

The anticoagulant effect of heparin is enhanced by concurrent treatment with THROMBATE III in patients with hereditary AT deficiency. Thus, in order to avoid bleeding, the dosage of heparin (or low molecular weight heparin) may need to be reduced during treatment with THROMBATE III.

Please see full Prescribing Information for THROMBATE III.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.

References: 1. Lloyd-Jones D, Adams RJ, Brown TM, et al; on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2010;121:e46-e215. 2. Tapson VF, Shirvanian S. Curr Med Res Opin. 2015;31(12):2297-2311. 3. Armstrong Institute for Patient Safety and Quality. https://www.hopkinsmedicine.org/armstrong_institute/improvement_projects/infections_complications/VTE/index.html. Accessed July 17, 2018. 4. Centers for Medicare & Medicaid Services and The Joint Commission. NQF-Endorsed Voluntary Consensus Standards for Hospital Care. Version 5.0b. In: Specifications Manual for National Hospital Inpatient Quality Measures. https://www.jointcommission.org/specifications_manual_for_national_hospital_inpatient_quality_measures.aspx. Published October 20, 2016. Accessed April 27, 2017. 5. Cohen AT, Tapson VF, Bergmann JF, et al; ENDORSE Investigators. Lancet. 2008;371(9610):387-394. 6. Tengborn L, Bergqvist D. Acta Chir Scand. 1988;154(3):179-183. 7. Pabinger I, Schneider B; Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol. 1996;16(6):742-748. 8. Bucciarelli P, Passamonti SM, Biguzzi E, et al. J Thromb Haemost. 2012;10:1783-1791. 9. Di Minno MND, Dentali F, Lupoli R, Ageno W. Circulation. 2014;129(4):497-503. 10. Kottke-Marchant K, Duncan A. Arch Pathol Lab Med. 2002;126(11):1326-1336. 11. Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F. Semin Thromb Hemost. 1991;17(3):304-312.